Related Experiment Video
Updated: Jun 19, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Dabigatran: clinical pharmacology].
1Groupe de Recherche sur la Thrombose, EA 3065, CIE3, CHU de Saint-Etienne, Université Jean Monnet, 42 055 Saint-Etienne, France. patrick.mismetti@chu-st-etienne.fr
Annales Francaises D'Anesthesie Et De Reanimation
|October 31, 2009
Summary
Dabigatran, a novel oral anticoagulant, shows promise for preventing blood clots in orthopedic surgery and atrial fibrillation patients. Phase II trials suggest optimal dosing regimens for further investigation in Phase III studies.
Area of Science:
- Pharmacology and Therapeutics
- Coagulation Cascade Inhibition
- Drug Development
Context:
- Dabigatran etexilate is an oral direct thrombin inhibitor.
- Established anticoagulants often require monitoring and have dietary restrictions.
- Novel oral anticoagulants offer potential advantages in patient management.
Purpose:
- To evaluate the pharmacokinetic profile and safety of dabigatran.
- To determine optimal dosing for venous thromboembolism (VTE) prophylaxis post-orthopedic surgery.
- To assess optimal dosing for preventing thromboembolic complications in atrial fibrillation (AF).
Summary:
- Dabigatran exhibits low bioavailability (7.5%) with rapid absorption and primarily renal elimination.
- Phase II trials suggest 150-220 mg once daily for VTE prophylaxis and 110-150 mg twice daily for AF thromboembolism prevention.
- No significant liver toxicity was observed, but severe renal/hepatic impairment are contraindications.
Impact:
- Dabigatran represents a new class of oral anticoagulants with potential for improved patient compliance.
- Phase II results provide a basis for Phase III trials to confirm efficacy and safety in larger populations.
- Further research will establish dabigatran's role in managing thrombotic disorders.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...